Ovarian Cancer Clinical Trials

Showing 861-880 of 1,169 trials

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00825201

RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving paclitaxel albumin-stabilized nanoparticle formulation directly into the abdomen may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of intraperitoneal paclitaxel albumin-stabilized nanoparticle formulation in treating patients with advanced cancer of the peritoneal cavity.

Ovarian CancerPeritoneal Cavity CancerUnspecified Adult Solid Tumor, Protocol Specific

City of Hope Medical Center27 participantsStarted Jan 2009

Duarte, California, United States • Seattle, Washington, United States

UNKNOWNNA

Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology

NCT03219242

Longitudinal prospective study on primary debulking surgery including bowel resection in advanced stage ovarian cancer patients using Caiman® technology

Ovarian Cancer

Catholic University of the Sacred Heart40 participantsStarted Jun 2016

Rome, Rome, Italy

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology

Related Searches

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.

Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.

Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer